1. Rubin JT: Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest 1993, 11: 460 - 472.
2. Lotze MT: Biologic therapy with interleukin-2: preclinical studies. In The Biologic Therapy of Cancer, edn 2. Edited by DeVita V, Hellman S, Rosenberg S. Philadelphia: JB Lippincott, 1991: 207 - 234.
3. Fyfe G, Fisher RI, Rosenberg SA, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
4. Riethmüller G, Schneider-Gödicke E, Schlimok G, Randomized trial of monoclonal antibody for adjuvant therapy of resected Duke’s C colorectal carcinoma. Lancet 1994, 343:117-83.SA, Sznol M, High-dose aldesleukin in renal cell carcinoma: long-term survival update. CancerJ Sci Am 1997, 3:S70-572.
5. Yang JC, Topalian SL, Parkinson D, Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994, 12:1572-1576.